Key Takeaway
You likely qualify for weight loss medication if your BMI is 30 or higher, or 27 or higher with a weight-related condition like diabetes, high blood pressure, or high cholesterol.
You qualify for GLP-1 weight loss medication if your BMI is 30 or higher, or 27-29.9 with a weight-related condition. The STEP trials demonstrated that 86% of participants with BMI 30+ achieved clinically significant weight loss on semaglutide, while the SURMOUNT studies showed 91% of participants lost 5% or more body weight on tirzepatide. These medications require medical supervision and aren't suitable for pregnant women or those with medullary thyroid carcinoma history.
Eligibility Criteria Explained
BMI of 30 or Higher
If your BMI is 30 or above, you meet the primary eligibility requirement for weight loss medication without any additional conditions needed. A BMI of 30 is classified as obese by the World Health Organization and CDC. For reference, a person who is 5'6" and weighs 186 pounds has a BMI of approximately 30.
BMI of 27-29.9 with a Comorbidity
If your BMI falls between 27 and 29.9, you can still qualify if you have one or more weight-related health conditions, including:.
- Type 2 diabetes or prediabetes
- High blood pressure (hypertension)
- High cholesterol or triglycerides (dyslipidemia)
- Obstructive sleep apnea
- Cardiovascular disease
- Non-alcoholic fatty liver disease (NAFLD)
- Polycystic ovary syndrome (PCOS)
- Osteoarthritis related to excess weight
Your provider evaluates your complete health picture, not just a single number BMI requirements for weight loss medication.
Clinical Evidence for GLP-1 Weight Loss Medications
The STEP clinical trial program evaluated semaglutide 2.4mg weekly in 4,567 participants across four studies. In STEP 1[1], participants lost an average of 14.9% body weight[1] over 68 weeks, with 83.5% achieving 5% weight loss and 66.1% achieving 10% weight loss. The medication works by activating GLP-1 receptors in the brain's appetite control centers, reducing food intake by approximately 35% and slowing gastric emptying by 70 minutes.
View data table
| Category | Search Volume Share (%) | Detail |
|---|---|---|
| Side Effects | 35 | Nausea, GI issues |
| Cost/Insurance | 28 | Pricing questions |
| Effectiveness | 22 | How much weight loss |
| Eligibility | 15 | BMI requirements |
Tirzepatide demonstrated even greater efficacy in the SURMOUNT trials, with participants losing up to 20.9% body weight at the highest 15mg dose over 72 weeks. The SURMOUNT-1[2] study showed that 91% of participants on tirzepatide 15mg achieved[2] 5% weight loss, compared to 35% on placebo. Tirzepatide targets both GLP-1 and GIP receptors, explaining its superior weight loss compared to single-receptor agonists like semaglutide and liraglutide.
Clinical Evidence
The STEP and SURMOUNT trials enrolled participants with BMI 30+ or BMI 27+ with comorbidities, establishing these as evidence-based qualification criteria. Participants with diabetes in STEP 2 lost 9.6% body weight while improving HbA1c by 1.6 percentage points.
Who Does Not Qualify
Weight loss medication isn't appropriate for everyone. You generally won't qualify if:
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →
- Your BMI is below 27: Current FDA guidelines don't support GLP-1 prescribing for individuals below this threshold.
- You're pregnant or breastfeeding: GLP-1 medications aren't safe during pregnancy. Semaglutide should be stopped at least 2 months before a planned pregnancy.
- You have a history of medullary thyroid carcinoma: GLP-1 medications are contraindicated in individuals with a personal or family history of medullary thyroid carcinoma or MEN 2 syndrome.
- You have a history of severe pancreatitis: While the risk is low, GLP-1 medications are generally avoided in patients with a significant pancreatitis history.
- You have a known allergy: Hypersensitivity to semaglutide or tirzepatide is a contraindication.
The Qualification Process
Getting evaluated for weight loss medication is straightforward, especially through telehealth:
- Health assessment: Complete a questionnaire covering your height, weight, medical history, current medications, and health goals.
- BMI calculation: Your provider calculates your BMI to confirm you meet the threshold.
- Medical review: A licensed provider reviews your full health profile, including any comorbidities, contraindications, and medication interactions.
- Provider decision: If you meet the criteria and no contraindications are present, the provider issues a prescription.
Through FormBlends, this entire process can be completed online, often within 24 to 48 hours how to get prescription weight loss medication online.
Do You Need Lab Work?
Some providers require recent lab work (within the past 6-12 months) before prescribing. Common tests include:
- thorough metabolic panel (CMP)
- Hemoglobin A1c (for diabetes screening)
- Lipid panel (cholesterol and triglycerides)
- Thyroid function tests
Not all telehealth platforms require labs upfront. Some may prescribe based on your health history and request labs at a follow-up visit.
Insurance vs. Cash-Pay Qualification
Insurance companies may have stricter qualification requirements than clinical guidelines. They often require:
- Documented prior attempts at diet and exercise
- Prior authorization
- Step therapy (trying cheaper medications first)
- Higher BMI thresholds
Cash-pay options through platforms like FormBlends follow standard medical guidelines without these added hurdles, making it faster and simpler to access treatment cheapest way to get semaglutide.
Medical References
- Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. [PubMed | ClinicalTrials.gov | DOI]
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. [PubMed | ClinicalTrials.gov | DOI]
- Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). Lancet. 2021;397(10278):971-984. [PubMed | ClinicalTrials.gov | DOI]
Frequently Asked Questions
Can I get weight loss medication if I am just slightly overweight?
If your BMI is between 25 and 26.9, you don't currently meet the standard criteria for GLP-1 medications. Some providers may consider off-label prescribing in specific cases, but this isn't common practice. Focus on lifestyle changes as the primary approach at this BMI range.
Do I need a referral from my primary care doctor?
No referral is needed. You can go directly to a telehealth platform or weight management provider. Any licensed physician, nurse practitioner, or physician assistant can evaluate and prescribe weight loss medication can nurse practitioner prescribe GLP-1.
Can teenagers qualify for weight loss medication?
Semaglutide (Wegovy) is FDA-approved for adolescents aged 12 and older with obesity . Prescribing in this age group should be done under close medical supervision, ideally by a pediatric or adolescent medicine specialist.
How quickly can I find out if I qualify?
Through telehealth platforms like FormBlends, you can typically complete the health assessment in 10-15 minutes and receive a provider decision within 24 to 48 hours. Some platforms offer same-day evaluations.
What if I was denied by my insurance?
Insurance denials are common for weight loss medications. You can appeal the denial, but many patients find it faster and more affordable to use a cash-pay telehealth platform with compounded semaglutide. This bypasses insurance requirements entirely cheapest way to get semaglutide.